TY - JOUR T1 - Development and validation of a clinical risk score to predict SARS-CoV-2 infection in emergency department patients: The CCEDRRN COVID-19 Infection Score (CCIS) JF - medRxiv DO - 10.1101/2021.07.15.21260590 SP - 2021.07.15.21260590 AU - Andrew D McRae AU - Corinne M Hohl AU - Rhonda J Rosychuk AU - Shabnam Vatanpour AU - Gelareh Ghaderi AU - Patrick M Archambault AU - Steven C Brooks AU - Ivy Cheng AU - Philip Davis AU - Jake Hayward AU - Eddy S Lang AU - Robert Ohle AU - Brian H. Rowe AU - Michelle Welsford AU - Krishan Yadav AU - Laurie J Morrison AU - Jeffrey J. Perry AU - Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) investigators for the Network of Canadian Emergency Researchers and the Canadian Critical Care Trials Group Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/19/2021.07.15.21260590.abstract N2 - Background Clinicians face decisions around the need for severe acute respiratory coronavirus 2 (SARS-CoV-2) testing, patient isolation, and empiric therapy when patients arrive in acute care hospitals. Our objective was to develop a risk score that can accurately quantify a patient’s probability of SARS-CoV-2 infection.Methods This observational study enrolled consecutive adults who presented to the emergency departments of 32 hospitals participating in Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) and were tested for SARS-CoV-2. We divided our study population by randomly assigning study sites into derivation (75%) and validation (25%) cohorts We pre-specified predictors and used multiple imputation for variables with incomplete data. In the derivation cohort, we fit models using logistic regression, with spline functions for continuous variables, to predict the primary outcome of a positive SARS-CoV-2 nucleic acid test. We used a fast step-down procedure to select a concise model. The final reduced model had points allocated to each variable based on their predictive strength. We then validated the model in the geographically distinct validation cohort.Findings We derived a ten-item CCEDRRN COVID-19 Infection Score using data from 21,743 patients. This score included variables from history and physical examination, and an indicator of local disease incidence. The score had a C-statistic of 0.838 with excellent calibration. We externally validated the rule in 5,295 patients. The score maintained excellent discrimination and calibration, and had superior performance compared to another previously published risk score.Interpretation The CCEDRRN COVID-19 Infection Score uses clinical characteristics and publicly available indicators of disease incidence to quantify a patient’s probability of SARS-CoV-2 infection. The score can identify patients at sufficiently high risk of SARS-CoV-2 infection to warrant isolation and empiric therapy prior to test confirmation, while also identifying patients at sufficiently low risk of infection that they may not need testing.Funding The network is funded by the Canadian Institutes of Health Research (447679), BC Academic Health Science Network Society, BioTalent Canada, Genome BC (COV024; VAC007), Ontario Ministry of Colleges and Universities (C-655-2129), the Saskatchewan Health Research Foundation (5357) and the Fondation CHU de Québec (Octroi #4007). These organizations are not-for-profit, and had no role in study conduct, analysis, or manuscript preparation.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicaltrials.gov, NCT04702945Clinical Protocols https://www.cmajopen.ca/content/9/1/E261 Funding StatementThe network is funded by the Canadian Institutes of Health Research (447679), BC Academic Health Science Network Society, BioTalent Canada, Genome BC (COV024; VAC007), Ontario Ministry of Colleges and Universities (C-655-2129), the Saskatchewan Health Research Foundation (5357) and the Fondation CHU de Quebec (Octroi #4007).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Alberta - University of Calgary Conjoint Health Research Ethics Board (REB20-0534); British Columbia - University of British Columbia Clinical Research Ethics Board (H20-01015); Manitoba - University of Manitoba Health Research Ethics Board (H2020:261); New Brunswick - Horizon Health Network Research Ethics Board (100890); Nova Scotia - Nova Scotia Health Authority Research Ethics Board (1025682); Ontario - Queens University Health Sciences & Affiliated Teaching Hospitals Research Ethics Board (2165); Quebec - Centre integre de sante et de services sociaux de Chaudiere-Appalaches(MP-23-2021-766); Saskatchewan - University of Saskatchewan Biomedical Research Ethics Board (1935);All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe CCEDRRN network accepts applications for access to data by external investigators, prioritizing data requests by network Members. https://canadiancovid19ednetwork.org/data-access/ ER -